Plexium

Plexium is a next-generation targeted protein degradation (TPD) company, leading the way in the rational design and discovery of monovalent protein degraders across a wide range of modalities. Plexium has built a comprehensive best-in-class TPD platform, powered by a proprietary high-throughput cell-based screening (uHTS) technology. Plexium’s next-generation TPD programs extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unravelling the boundless possibilities of true drug-like protein degraders.

https://www.plexium.com/

Team Member
more about
Therese Liechtenstein
Investment Director
Latest News Entry
2021/11/04
Plexium Appoints Percival Barretto-Ko as President and Chief Executive Officer

Plexium Inc. announced the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer and a member of the Board of Directors

2021/01/21
Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders

Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders

  • Company also announces appointment of biotech veteran Mike Grey as Chairman of the Board
2019/10/17
Plexium Launches with $28 Million in Series A Financing

Funds will help advance Plexium’s DELPhe platform to discover novel E3 ligase-modulating therapeutics to treat cancer and neurodegenerative diseases

all portfolio news